Risks of carpal tunnel syndrome and carpal tunnel release surgery in users of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A target trial emulation study
Authors' conclusion
In patients with type 2 diabetes mellitus, SGLT2is seem to decrease the risk of carpal tunnel syndrome and the need for carpal tunnel release surgery. Prospective studies are required to confirm our results.
Study context
- Population
- Patients with T2D prescribed SGLT2is or GLP-1RAs; SGLT2is: mean age 59.6 years, 46 % women; GLP-1RAs: mean age 59.5 years, 45.9 % womenpropensity score matched
- Participants
- 65,464 vs 65,464
- Exposure
- SGLT2i vs GLP-1 RA new users
- SGLT2isn = 65,464
- GLP-1RAsn = 65,464reference
- Outcome
- Risk of carpal tunnel syndrome and risk of carpal tunnel release surgery
Methodological detailsnew-user active comparator, target trial emulation, propensity score matching, TriNetX platform
- New-user active comparator
- Target trial emulation
- Propensity score matching
- TriNetX platform
Main finding
As reported in the abstract
Carpal tunnel syndrome
SGLT2is vs GLP-1RAsHazard ratio (95 % CI)
Carpal tunnel syndrome
0.928(0.869–0.991)
Carpal tunnel release surgery; significantly lower with SGLT2is
0.840(0.726–0.971)
Observational data: associations, not effects.
Original publication
Risks of carpal tunnel syndrome and carpal tunnel release surgery in users of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A target trial emulation study. Diabetes Metab. Published 20 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →